Stryker said reported net sales for Q4 increased 10.7% to $6.4 billion, and full-year reported net sales increased 10.2% to $22.6 billion. Organic net sales increased 10.2% for Q4 and the full year.

1. 01

   Stryker said reported net sales for Q4 increased 10.7% to $6.4 billion, and full-year reported net sales increased 10.2% to $22.6 billion. Organic net sales increased 10.2% for Q4 and the full year.

2. 02

   The company said reported net earnings for Q4 decreased 52.2% to $0.5 billion and reported EPS decreased 52.7% to $1.41. It explained that reported net earnings included non-cash goodwill and other impairments of $818 million related to the Spine business.

3. 03

   Stryker said adjusted EPS for Q4 increased 15.9% to $4.01 and adjusted operating income margin was 29.2%. For the full year, adjusted EPS increased 15.0% to $12.19 and adjusted operating income margin was 25.3%.

4. 04

   The company said it expects organic net sales growth for 2025 to be in the range of 8.0% to 9.0% and adjusted net earnings per diluted share to be in the range of $13.45 to $13.70. It said the Inari acquisition is anticipated to close toward the end of February and Inari is expected to deliver approximately $590 million of sales in the 2025 stub period on a constant currency basis.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.